Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart artery study tests smarter imaging to prevent attacks

NCT ID NCT01881555

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a special pressure wire measurement (FFR) to standard angiography helps doctors decide the best treatment for people with multiple blocked heart arteries. Over 900 patients were randomly assigned to get either angiography alone or angiography plus FFR to guide their care. The goal was to see if the FFR-guided approach reduces major heart problems like death, heart attack, or the need for more procedures within one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
invasive coronary angiography with or without fractional flow reserve (FFR) measurement
What this could lead to
If successful, this could show that adding FFR testing to angiography helps doctors choose better treatments, reducing heart attacks and deaths in people with multiple blocked arteries.
What could go wrong
This trial is completed, but the results may not apply to all patients or settings. FFR testing adds time and cost, and the benefit may be small or limited to certain subgroups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

941 people

The number who actually took part.

Start date

May 2013

Finished

Jun 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \> 18 * referred to the cardiologist for one of the following medical condition : * ST segment elevation myocardial infarction evolving for more than 7 days after revascularization of culprit coronary artery or * no ST elevation acute coronary syndrome with or without troponin (T or I) elevation and medically stabilized for at least 12 hours or * stable angina (CCS I, II or III) or * chest pain diagnosis with suspicion of CAD or with ischemia certificated by non invasive tests. * patients with at least 2 vessel disease (≥50% stenosis on angiography) including the left anterior descending coronary artery or with single vessel disease on left main coronary artery * Patient willing and able to provide informed, written consent * Patient not under legal protection * Patient benefiting from the French Health Insurance Exclusion Criteria: * Pregnancy, childbearing, absence of effective contraception * Previous coronary bypass surgery * Planned associated valvular surgery * Life expectancy \< 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multivessel coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Angina, Stable coronary artery disorder intermediate coronary syndrome ST-elevation myocardial infarction vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multivessel coronary artery disease Patients with ST-elevated myocardial infarction Revascularization of culprit coronary artery Stable angina Unstable angina or stabilized non-ST elevated myocardial infarction Vessel disease

Contacts and locations

Locations

  • HOSPICES

    Lyon, 69002, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.